Precigen (NASDAQ:PGEN) Shares Down 6.5% – Here’s What Happened

Posted by George Bondi on Oct 7th, 2026

Precigen, Inc. (NASDAQ:PGEN – Get Free Report) shares were down 6.5% during trading on Monday. The company traded as low as $8.02 and last traded at $7.9860. 1,633,128 shares changed hands during trading, a decline of 65% from the average session volume of 4,678,389 shares. The stock had previously closed at $8.54.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. HC Wainwright raised their target price on Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. B. Riley Financial initiated coverage on shares of Precigen in a research report on Friday, September 25th. They set a “buy” rating and a $12.00 price target for the company. Zacks Research raised shares of Precigen from a “hold” rating to a “strong-buy” rating in a report on Wednesday, August 5th. Wall Street Zen raised shares of Precigen from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $13.67.

Read Our Latest Analysis on Precigen

Precigen Trading Down 2.5%

The company has a current ratio of 4.58, a quick ratio of 3.89 and a debt-to-equity ratio of 2.15. The stock has a market capitalization of $2.69 billion, a price-to-earnings ratio of -7.26 and a beta of 0.92. The firm has a 50-day moving average of $7.15 and a 200 day moving average of $5.41.

Precigen (NASDAQ:PGEN – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The company had revenue of $54.98 million during the quarter, compared to analyst estimates of $27.98 million. The company’s revenue for the quarter was up 6322.7% compared to the same quarter last year. As a group, equities analysts predict that Precigen, Inc. will post 0.24 EPS for the current fiscal year.

Insider Activity at Precigen

In related news, CFO Harry Thomasian, Jr. sold 100,000 shares of the stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $6.06, for a total value of $606,000.00. Following the completion of the transaction, the chief financial officer owned 254,535 shares in the company, valued at $1,542,482.10. This represents a 28.21% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey B. Kindler sold 185,000 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the transaction, the director directly owned 17,100 shares in the company, valued at approximately $127,224. The trade was a 91.54% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 401,511 shares of company stock worth $2,801,508 over the last ninety days. 41.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Engineers Gate Manager LP raised its holdings in Precigen by 207.8% during the second quarter. Engineers Gate Manager LP now owns 40,880 shares of the biotechnology company’s stock worth $233,000 after purchasing an additional 27,600 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Precigen during the 2nd quarter valued at $73,000. Squarepoint Ops LLC increased its position in shares of Precigen by 462.8% during the 2nd quarter. Squarepoint Ops LLC now owns 353,272 shares of the biotechnology company’s stock valued at $2,014,000 after purchasing an additional 290,505 shares during the period. Arizona State Retirement System raised its stake in shares of Precigen by 10.5% in the 2nd quarter. Arizona State Retirement System now owns 53,713 shares of the biotechnology company’s stock worth $306,000 after buying an additional 5,086 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Precigen in the 2nd quarter worth $227,000. 33.51% of the stock is currently owned by institutional investors.

Precigen Company Profile

(Get Free Report)

Precigen, Inc (NASDAQ:PGEN) is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for serious diseases, including cancer, infectious diseases and certain immune-related conditions. The company uses its proprietary technologies to engineer therapies intended to improve treatment precision, durability and accessibility.

Precigen’s pipeline has included PRGN-2012, an investigational immunotherapy for recurrent respiratory papillomatosis, as well as programs based on its UltraCAR-T platform for cancer treatment.